Načítá se...
A single-institution experience with bevacizumab in the treatment of metastatic colorectal cancer and in conjunction with liver resection
BACKGROUND: Bevacizumab is active in the treatment of metastatic colorectal cancer (mCRC). However, efficacy of bevacizumab has predominantly been evaluated on selected patients with relatively good performance status and minor comorbidities. We evaluated the efficacy and safety of bevacizumab in un...
Uloženo v:
| Hlavní autoři: | , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4085307/ https://ncbi.nlm.nih.gov/pubmed/25061319 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S63739 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|